)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
CareDx
CareDx (CDNA) investor relations material
CareDx Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary29 Oct, 2026
Executive summary
Q3 revenue was $139.362M, up 39% YoY; testing volume rose 51% to 75,900, and adjusted EBITDA was $30.496M, or 22% of revenue.
FY2026 revenue guidance increased to $520M–$530M and adjusted EBITDA guidance to $90M–$100M.
Growth spanned Testing Services and Patient and Digital Solutions, with Specialty Oncology contributing after the Naveris acquisition.
Financial highlights
Q3 Testing Services revenue was $119.2M, up 65% YoY; Patient and Digital Solutions revenue was $20.2M, up 31%.
GAAP net income was $19.292M versus $1.675M in Q3 2025; diluted GAAP EPS was $0.35 versus $0.03.
Non-GAAP gross margin was 74%, versus 71% a year earlier; adjusted EBITDA was $30.496M versus $15.299M.
Q3 operating cash flow was $12.718M; after $1.615M of capital expenditures, free cash flow was $11.103M.
Q3 Testing Services revenue included $15M of prior-period revenue versus $6M a year earlier; excluding it, growth was ~58% YoY.
Outlook and guidance
FY2026 revenue guidance rose to $520M–$530M from $490M–$500M; the $525M midpoint implies 38% YoY growth.
FY2026 adjusted EBITDA guidance rose to $90M–$100M from $66M–$78M; the $95M midpoint equals 18% of revenue.
Q4 revenue guidance is $131M–$141M, with a $136M midpoint; adjusted EBITDA guidance is $16M–$26M.
Q4 testing volume guidance is 76K–80K tests, including 61K–63K transplant and 15K–17K Specialty Oncology tests; non-GAAP gross margin is modeled at 71%–72%.
AlloHeme and HistoMap Kidney target CLIA readiness before year-end 2026 and commercial launches or broader availability in 2027; AlloHeme is targeted for Q1 launch.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from CareDx
- Q2 2026 revenue up 52% to $132M; net income $111M; guidance raised on strong growth.CDNA
Q2 2026 - All agenda items, including director elections and equity plan amendment, were approved.CDNAAGM 2026
- Precision diagnostics focus, Naveris acquisition, and pipeline expansion drive growth and profitability.CDNAGoldman Sachs 47th Annual Global Healthcare Conference 2026
- Stockholders to vote on 2025 executive compensation, with clarified bonus calculation methods.CDNAProxy filing
- Q1 revenue up 39%, pipeline expands with Naveris and AlloHeme, driving future growth.CDNAJefferies Global Healthcare Conference 2026
- Key votes include director elections, auditor ratification, and expanding the equity incentive plan.CDNAProxy filing
- Q1 2026 revenue up 39% to $118M, net income positive, guidance raised, and major M&A moves.CDNAQ1 2026
- 2025 revenue up 14% to $380M; 2026 guidance $420–$444M with strong segment growth.CDNAQ4 2025
- Q3 revenue up 23%, guidance raised, profitability improves, and Medicare coverage reaffirmed.CDNAQ3 2024
Next CareDx earnings date
Q4 202626 Feb, 2027
CareDx
Next CareDx earnings date
Q4 202626 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers UNITY HEART, a precision medicine platform to diagnose the degree of cardiac allograft rejection without the need for a confirmatory endomyocardial biopsy; and UNITY OV, an automated whole blood donor screening system to detect donor-derived cell-free DNA prior to solid organ transplantation and non-invasive as well as categorical monitoring of allograft injury. The company also provides AlloMap heart transplant test that measure mRNA transcripts from 22 genes expressed in immune cells and fibroblasts for personalized patient management; and AlloSure kidney transplant test to measure the amount of a donor specific DNA in a recipient’s bloodstream.